Please login to the form below

Not currently logged in
Email:
Password:

Medicxi appoints former GSK chair Moncef Slaoui

He joins the life science investment firm as a partner

Moncef SlaouiLondon, UK-based life science investment group Medicxi has appointed former GSK chairman of pharmaceutical R&D, vaccines Dr Moncef Slaoui as its new partner.

Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.

He previously spent 28 years at GSK, and retired earlier this year.

He said: “Having developed a strong relationship with the Medicxi founders over many years, it is an exciting time to join the team, with funds available to invest not only in early stage assets but also to building innovative companies through clinical development and market entry.

“I am looking forward to making an active contribution to selecting and leading investments, and to supporting ambitious entrepreneurs to develop medicines hat ultimately make a difference to patients.”

His new role will see him at the helm of sponsoring and supporting investments, undertaking due diligence and valuations for the group’s venture fund and growth fund, and he will support investee companies in their development.

Michéle Ollier, co-founder and partner at Medicxi, said: “Moncef has made a tremendous contribution through his role on our SABs and we look forward to his continued energetic and insightful contribution as a partner at Medicxi.”

2nd October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics